New Delhi, India, July 03, 2015 --(PR.com
)-- DelveInsight, the leading Business Consultant and Market Research firm is pleased to declare the launch of its report, Chimeric Antigen Receptor (CAR)-T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2015. It is anticipated that CAR-T cell therapy would be a major breakthrough in Immuno-Oncology.
The Chimeric Antigen Receptor (CAR)-T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2015 Report gives insights on 35 products targeting 20 different antigens and 9 different technologies. It also includes around 35+ companies which are active in this field. The report provides in-depth analysis on the CAR-T cell profiles covering pre-clinical and clinical studies, collaborations details and deal values, technologies and targeted antigens. The report also provides the CAR-T licensing opportunities, acquisitions, market drivers and barriers followed by SWOT Analysis.
Key Topics Covered:
· Collaborations and Deals
· Licensing Opportunities
· Pipeline Scenario and product profiles
· CAR-T Technologies and Targeted Antigens
· Adverse effects of CAR-T
· Market Drivers and Barriers
DelveInsight is offering the Report at a price of USD 1,750 as a single user license, USD 3,500 as a site license and USD 5,000 as a Global/Enterprise License. This Report will help to identify emerging players with potentially strong product information, licensing opportunities and helps you to create effective counter-strategies to gain competitive advantage.
For more information on this report, email at firstname.lastname@example.org